RFL - NYSE
Rafael Holdings, Inc.
$1.39
+7.0%Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
At a Glance
Live SnapshotRafael Holdings, Inc. Management Team
Mr. Howard S. Jonas
Chief Executive Officer, President, Founder & Executive Chairman
Compensation
$44,000
Mr. David A. Polinsky Esq.
Chief Financial Officer
Compensation
$429,653
Mr. Joshua M. Fine
Chief Operating Officer
Ms. Joyce J. Mason Esq.
Corporate Secretary
Rafael Holdings, Inc. Insider Positioning
During the last 12 months, insiders have purchased $15.74M worth of RFL shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
12.3M
15.74M
0
0.00
+15.7M
+$15.74M
Top Buyers
Jonas Howard S
Director, 10 Percent Owner, Officer: Exec Chairman, Ceo & President
$15.74M
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $15.74M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
1 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Unanimous insider buying: Zero selling combined with active buying is rare and typically very bullish. Insiders appear to see significant upside with limited downside risk.
SEC Filings
RFL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | November 18, 2025 | January 08, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | November 19, 2024 | January 09, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | November 20, 2023 | January 10, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | November 28, 2022 | January 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | November 24, 2021 | January 19, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | November 23, 2020 | January 13, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | November 21, 2019 | January 15, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | November 27, 2018 | January 10, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.